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Dear Editor:
Androgen deﬁciency is an endocrine abnormality that is
common in male patients with chronic kidney disease and
affects 50%–75% of patients treated with haemodialysis.1,2 Its
clinical signiﬁcance is not well known, although various cross-
sectional studies have linked low testosterone levels to sexual
dysfunction, anaemia, loss of muscle mass, increase in car-
diovascular risk and greater mortality.2–5
Androgens in pharmacological doses have effects on
anaemia and nutritional parameters in patients treated with
regular haemodialysis.6 However, few studies have analysed
the effect of treating hypogonadism from renal failure with
physiological doses of testosterone, and their results have
been controversial.7,8
In this study we  present the preliminary data for the
results obtained following correction of androgen deﬁciency
in patients treated with haemodialysis.
We deﬁned androgen deﬁciency as a total serum testos-
terone concentration lower than 300 ng/dl and an unbound
testosterone concentration lower than 225 pMol/l. Testos-
terone circulates in plasma bound to proteins (especially
albumin and a transport globulin [sex hormone-binding glob-
ulin, or SHBG]); only 1%–3% circulates unbound. A uraemic
patient may have an abnormal SHBG concentration.9 There-
fore, in patients with chronic kidney disease it is advisable to
conﬁrm testosterone deﬁciency by determining the concen-
tration of unbound testosterone, especially in cases with a
total testosterone level that is low but close to the lower limit of
the normal range. Unbound testosterone was calculated based
10on levels of total testosterone, SHBG and albumin.
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The study was conducted in male patients treated with
regular haemodialysis for more  than 6 months who  were in
a stable clinical situation and had not required admission in
the last 3 months. All draws for laboratory testing were per-
formed immediately before the ﬁrst haemodialysis session of
the week.
Of the 39 patients analysed, 20 (51%) had a total testos-
terone concentration lower than 300 ng/dl, all had an unbound
testosterone concentration lower than 225 pMol/l, and all
were diagnosed with androgen deﬁciency. Twelve of these
20 patients agreed to participate in the study and granted
their written consent. Patients were randomly assigned to the
treatment group (6 patients who received testosterone by the
transdermal route: one sachet of 5 g of gel containing 50 mg
of testosterone daily for 3 months) or the control group (the
other 6 patients). The dose of testosterone administered to the
treatment group was the minimum initial dose recommended
in the medicine’s summary of product characteristics.
Patients in the treatment group had a younger age (67 ± 4
vs 75 ± 9 years; p = 0.182), and at baseline there were no
differences between the two groups in terms of the other
parameters analysed. Table 1 shows the changes in these
parameters. The unbound and total serum testosterone con-
centration increased in all patients treated, but it only reached
the normal range in 4 (Fig. 1). Neither of the 2 groups of patients
showed a change in concentrations of total cholesterol, HDL
cholesterol, LDL cholesterol or triglycerides (data not shown).
The prevalence of androgen deﬁciency in male patients
from the haemodialysis unit was 51%. This ﬁgure was similarez Lucas M, Delgado Yagüe M, García Cano AM,  Lian˜o García F.
plementos de testosterona. Resultados preliminares. Nefrologia.
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Table 1 – Effect of testosterone replacement therapy.
Treatmen
Baseline 3 m
Total testosterone [300–900 ng/dl] 188 (54) 335
Unbound testosterone [>225 pMol/l] 147 (48) 279
FSH [1–12 mIU/l] 10.4 (12.7) 7.4
LH [1.1–8.8 mIU/l] 14.9 (15.9) 7.5
Haemoglobin [g/dl] 11.4 (1) 11.2
EPO alfa [IU/kg/week] 103 (82) 69
Albumin [g/dl] 4  (0.3) 4.5
The normal value is in square brackets and the standard deviation is
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ig. 1 – Treatment group: changes in total serum
estosterone level, in each case.
he summary of product characteristics, increased the serum
evel of the hormone and had an inhibitory effect on the
ypothalamic–pituitary axis. In 4 of the 6 patients treated,
he total testosterone concentration exceeded the lower limit
f the range considered to be normal, but the dose adminis-
ered was not sufﬁcient to reach the mean levels of this range
300–900 ng/ml).
The increases in testosterone concentration achieved,
hough small, were associated with a reduction in needs for
rythropoietin alfa and a modest but signiﬁcant increase in
lbumin concentration.
This was a preliminary study, conducted in a small number
f patients during a short follow-up period, but its results sug-
est that androgen deﬁciency in patients with chronic kidney
isease may be clinically signiﬁcant, with repercussions for
naemia and nutrition, as some cross-sectional studies have
uggested. They also suggest that replacement therapy may
ave beneﬁcial effects on these complications.
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